Production (Stage)
Ensysce Biosciences, Inc.
ENSC
$2.07
-$0.07-3.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.22M | 5.21M | 4.42M | 1.44M | 1.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.22M | 5.21M | 4.42M | 1.44M | 1.75M |
| Cost of Revenue | 8.33M | 7.22M | 5.65M | 5.87M | 6.57M |
| Gross Profit | -2.10M | -2.01M | -1.23M | -4.44M | -4.82M |
| SG&A Expenses | 4.75M | 4.72M | 5.08M | 5.23M | 5.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.08M | 11.94M | 10.73M | 11.10M | 11.75M |
| Operating Income | -6.85M | -6.73M | -6.31M | -9.66M | -10.00M |
| Income Before Tax | -6.82M | -7.99M | -7.93M | -11.28M | -11.55M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.82 | -7.99 | -7.93 | -11.28 | -11.55 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 100.00 | 1.10K | 2.30K | 9.40K |
| Net Income | -6.82M | -7.99M | -7.93M | -11.28M | -11.54M |
| EBIT | -6.85M | -6.73M | -6.31M | -9.66M | -10.00M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.63 | -13.45 | -27.50 | -41.58 | -52.98 |
| Normalized Basic EPS | -4.15 | -8.41 | -17.19 | -25.98 | -33.07 |
| EPS Diluted | -6.63 | -13.45 | -27.50 | -41.58 | -52.98 |
| Normalized Diluted EPS | -4.15 | -8.41 | -17.19 | -25.98 | -33.07 |
| Average Basic Shares Outstanding | 3.88M | 2.86M | 1.83M | 1.38M | 943.60K |
| Average Diluted Shares Outstanding | 3.88M | 2.86M | 1.83M | 1.38M | 943.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |